The Debate: Optimizing Concentrations Dextrose Prolotherapy for Regenerative Healing
Exploring Prolotherapy: A Debate on Dextrose Concentrations
Prolotherapy, a regenerative treatment involving the injection of dextrose solutions to stimulate tissue repair, has gained attention for its potential in managing musculoskeletal pain. I am the faculty lead of the Regenerative Medicine Honor’s Track at Sonoran University of Health Sciences. As part of completing their competencies for graduation this quarter, the 2024 Regenerative Medicine Honor’s Track students, Alanna Ullery, Makenzi Cavanaugh, and Andrew Otten, delved into the efficacy of varying dextrose concentrations in prolotherapy, specifically 10-15% (Kenzie), 15-20% (Lanny), and 20-25% (Drew).
The Role of Dextrose Concentration in Healing
The discussion highlighted that higher dextrose concentrations might enhance the regenerative response by promoting greater inflammation, which is essential for healing. However, increased concentrations could also lead to more discomfort post-injection.
Conversely, lower concentrations may result in less post-procedural pain but might require more sessions to achieve the desired therapeutic outcomes. This balance between efficacy and comfort is a key consideration when designing treatment plans.
Personalized Treatment Plans Are Key
This debate underscores the importance of personalized treatment plans in prolotherapy. Factors such as the patient’s pain tolerance, the specific condition being treated, and their overall health should guide the selection of dextrose concentration.
Collaborating with a healthcare provider experienced in regenerative medicine is crucial to determine the most appropriate approach for each individual.
Watch the Full Debate
For a more in-depth understanding of the science and clinical considerations behind prolotherapy, watch the full debate here.
References
1. Yellin Y, Shulman D, Hasegawa A, et al. The effects of hypertonic dextrose injection on connective tissue and nerve conduction through the rabbit carpal tunnel. *J Orthop Res*. 2021;39(2):421-430. doi:10.1002/jor.24833.
2. Tsai SW, Hsu YJ, Lee MC, et al. Effects of dextrose prolotherapy on contusion-induced muscle injuries in mice. *Int J Med Sci*. 2018;15(12):1251-1259. doi:10.7150/ijms.26795.
3. Park YS, Lim SW, Lee IH, et al. Intra-articular injection of a nutritive mixture solution protects articular cartilage from osteoarthritic progression induced by anterior cruciate ligament transection in mature rabbits: a randomized controlled trial. *Arthritis Res Ther*. 2007;9(1):R30. doi:10.1186/ar2140.
4. Topol GA, Podesta LA, Reeves KD, et al. Chondrogenic effect of intra-articular hypertonic-dextrose (prolotherapy) in severe knee osteoarthritis. *PM R*. 2016;8(11):1072-1082. doi:10.1016/j.pmrj.2016.04.004.
5. Dumais R, Benoit C, Dumais A, et al. Long-term effects of dextrose prolotherapy for anterior cruciate ligament laxity: preference of low (10%) versus high (25%) dextrose concentration. *Pain Med*. 2012;13(8):990-1000. doi:10.1111/j.1526-4637.2012.01436.x.
6. Reeves KD, Hassanein KM. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without anterior cruciate ligament laxity. *Altern Ther Health Med*. 2000;6(2):68-80.
7. Jensen KT, Rabago DP, Best TM, et al. Early inflammatory response of knee ligaments to prolotherapy in a rat model. *J Orthop Res*. 2008;26(6):816-823. doi:10.1002/jor.20572.
8. Lyftogt J. Subcutaneous prolotherapy treatment of refractory knee, shoulder, and lateral elbow pain. *Australas Musculoskeletal Med*. 2007;12(2):110-112.
9. Chen CP, Lee SW, Lee MR, et al. Effects of prolotherapy with dextrose and morrhuate sodium on degenerative cartilage: Histologic and molecular analysis in an animal model. *J Orthop Surg Res*. 2018;13(1):171. doi:10.1186/s13018-018-0882-y. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5999508/.
10. Mohammed SI, Kumar PS, Babu CS, et al. A review on the clinical and pharmacological uses of prolotherapy in the treatment of musculoskeletal pain. *Int J Pharm Clin Res*. 2022;16(2):421-425. Available from: http://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue2,Article267.pdf.
11. Hauser RA, Hauser MA, Cukla J. About prolotherapy history: Its origin, rise, and current practice. *Prolotherapy Website*. 2024. Available from: https://www.prolotherapy.com/about-prolotherapy-history.html.
12. Lee GW, Lee S, Kim HJ. Efficacy of dextrose prolotherapy for management of chronic musculoskeletal pain: A systematic review and meta-analysis. *Pain Physician*. 2022;25(2):E215-E227. doi:10.36076/ppj.2022/25/E215. Available from: https://pubmed.ncbi.nlm.nih.gov/35257594/.